EGEN-001 + FOLFIRI

**EGEN-001 + FOLFIRI** is a combination therapy utilizing EGEN-001—an investigational gene therapy—alongside FOLFIRI, a standard chemotherapy regimen consisting of irinotecan, fluorouracil (5-FU), and folinic acid (leucovorin)[2][3][4][7]. EGEN-001 is designed for gene therapy delivery, encoding human interleukin-12 (IL-12), and is under investigation for use in cancer treatment, specifically targeting mechanisms involved in tumor immunomodulation and anti-cancer immune activation. FOLFIRI acts by cytotoxic mechanisms: - **Irinotecan** inhibits topoisomerase I, preventing DNA replication. - **Fluorouracil** (5-FU) is an antimetabolite disrupting DNA and RNA synthesis. - **Folinic acid** enhances the efficacy of 5-FU by stabilizing its interaction with target enzymes[2][3][4][7]. Use of EGEN-001 + FOLFIRI, where studied, aims to leverage both direct tumor cell kill (chemotherapy) and immune engagement (gene therapy), with primary indications in gastrointestinal and colorectal cancers.

Other names

irinotecan with fluorouracil and folinic acidirinotecan de Gramontirinotecan modified de Gramont